Bard hernia mesh lawsuit MDL 2846: where the litigation actually stands after the $1+ billion settlement framework

The Bard hernia mesh litigation represents one of the largest pharmaceutical and medical device mass torts currently in settlement administration. MDL 2846 (In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation), centralized in the U.S. District Court for the Southern District of Ohio before Judge Edmund A. Sargus, Jr. (with Magistrate Judge Kimberly A. Jolson), consolidates approximately 23,695 cases as of March 2026. The case count peaked around 24,078 in mid-2025 and has remained relatively stable as settlement administration proceeds. The defendants are C.R. Bard, Inc. and Davol, Inc. — both now owned by Becton, Dickinson and Company (BD), which acquired Bard in 2017.

The litigation entered its major settlement phase in October 2024 when Becton Dickinson announced a multi-billion dollar global settlement framework covering approximately 38,000 claims. The framework operates on a points-based allocation system where each plaintiff's compensation is determined by the specific severity of injuries, the long-term health impact, age at injury, lost wages, and other case-specific factors. The Qualified Settlement Fund (QSF) was established in January 2025 with Wells Fargo serving as escrow agent and court-appointed Special Masters administering claims. The original deadline for submitting settlement documentation was March 17, 2025. The Intensive Settlement Process (ISP) is scheduled to launch in January 2027 under court-appointed Special Masters, with the ISP timeline running through June 2029.

The bellwether trial results that produced the settlement framework were mixed but trended favorably for plaintiffs over time. The first bellwether (Johns v. C.R. Bard, April 2022) produced a defense verdict. The second bellwether (Milanesi) produced a $250,000 plaintiff verdict. The third bellwether (Stinson v. Davol, November 2023) produced a $500,000 plaintiff verdict — the jury found Bard liable for failure to warn doctors about the potential risks of the hernia mesh product. The state court track was more decisive — Trevino v. Davol/Bard in Rhode Island state court produced a $4.8 million verdict in 2022 (reduced to $4.55 million on post-trial motions). The combination of plaintiff verdicts in MDL bellwethers and the substantial Rhode Island state court verdict created the leverage that produced the global settlement framework.

The substantive theory in the litigation focuses on polypropylene mesh material problems. Plaintiffs allege the polypropylene used in Bard hernia mesh products isn't suitable for permanent implantation, leading to material degradation, mesh migration, adhesion to internal organs, infection, and chronic pain. Internal corporate documents produced in discovery have shown that Bard had information about polypropylene problems years before the litigation began. The failure-to-warn theory has been the most successful approach at trial — Bard knew about the risks and didn't adequately warn doctors who implanted the products in patients.

This is the science behind the polypropylene mesh theory, the procedural history of MDL 2846 through the global settlement framework, the eligibility framework for current and prospective plaintiffs, the points-based allocation system, and the strategic considerations for plaintiffs navigating the settlement process or considering new claims.

What hernia mesh is and the alleged problem

Hernia repair surgery often uses surgical mesh to support the abdominal wall during healing:

Purpose of mesh. During hernia repair, surgeons use mesh to:

Reinforce the abdominal wall at the hernia site
Distribute pressure to prevent recurrence
Provide permanent structural support
Allow tissue to grow into and around the mesh

Polypropylene material. Most hernia mesh products use polypropylene, a synthetic polymer. The material is chosen for:

Strength and durability
Cost-effectiveness
Long history in medical applications
FDA-cleared status for surgical use

The alleged problems with polypropylene mesh:

Material instability when permanently implanted. Plaintiffs allege that polypropylene becomes unstable in the body over time. The material may:

Degrade gradually
Become brittle
Develop tears or fragmentation
Lose structural integrity
Cause inflammatory response in surrounding tissue

Mesh migration. The mesh can move from the original implantation site:

Wandering through abdominal cavity
Adherence to wrong tissues
Pressure on adjacent organs
Mechanical damage to organs

Adhesion to organs. The mesh can adhere to:

Intestines (causing bowel obstruction)
Bladder (causing urinary issues)
Other abdominal organs (causing various complications)
Abdominal wall tissue (causing chronic pain)

Contraction and curling. The mesh can contract over time:

Loss of effective coverage area
Curling into ball formations
Creation of stress points
Recurrent hernias as mesh fails

Infection. Bacterial colonization of the mesh:

Difficult to treat with antibiotics
Often requires mesh removal
Can cause systemic infection
Permanent complications even after treatment

Internal corporate knowledge. Discovery in MDL 2846 produced internal Bard documents showing the company had information about polypropylene problems for years. Engineering analyses, medical literature reviews, and adverse event tracking documented the risks. The information wasn't adequately communicated to physicians or patients.

The implicated products

Various Bard hernia mesh products are at issue in MDL 2846:

Ventralex Hernia Patch. A central product in the litigation. Polypropylene mesh with expandable ring. The Trevino state court verdict ($4.8 million) involved Ventralex.

Composix Hernia Patch series. Including Composix E/X and Composix LIP. Multiple plaintiffs experienced complications.

Per-Fix Plug Mesh. Triangular polypropylene mesh. Stinson MDL bellwether ($500,000 plaintiff verdict) involved Per-Fix mesh.

3D Max series. Three-dimensional mesh designed for inguinal hernia repair.

Sepramesh IP Composite. Composite mesh combining materials.

Various other Bard/Davol products. The MDL covers a broad range of polypropylene mesh products.

Historical context. Earlier hernia mesh litigation included:

Composix Kugel patch (MDL 1842): ~2,600 settled in 2011, ~6,000 settled in 2014, MDL closed in 2017 with approximately $184 million in total settlements
The Kugel patch had a specific design issue (expandable ring failure)
The current MDL 2846 addresses broader polypropylene mesh issues across multiple product lines

The alleged injuries

Plaintiffs in MDL 2846 allege various injuries:

Chronic pain. Persistent pain at the hernia repair site, often years after implantation. Pain may be:

Localized at the surgical site
Radiating to adjacent areas
Worsening with activity
Resistant to typical pain management

Bowel obstruction. Mesh adherence to or migration into the intestines:

Partial or complete obstruction
Emergency hospitalization
Surgical intervention required
Risk of bowel perforation

Infection. Bacterial infection of the mesh:

Persistent infection resistant to antibiotics
Often requires complete mesh removal
Septic complications
Repeat surgical interventions

Organ perforation. Mesh damage to:

Intestines (bowel perforation)
Bladder
Other abdominal organs

Recurrent hernias. Despite the mesh, the hernia returns:

Mesh failure or migration
Need for additional surgery
Often more complex repair than original
Sometimes worse outcomes than no mesh

Adhesions and scarring. Internal scar tissue caused by mesh-tissue interaction:

Chronic discomfort
Functional limitations
Difficulty with future abdominal surgeries

Mesh fragments. Pieces of mesh that:

Migrate to other locations
Require surgical retrieval
Cause secondary complications

Need for revision surgery. Many plaintiffs require:

Mesh removal procedures
Replacement with different mesh (if hernia recurs)
Complex reconstructive surgery
Multiple revision attempts

Long-term complications. Even after revision:

Permanent functional limitations
Chronic pain
Restricted activity
Quality of life impact

The injury severity varies substantially across plaintiffs. The settlement framework's points-based system specifically accounts for injury severity.

The procedural history of MDL 2846

The litigation has developed over years:

2018. Judicial Panel on Multidistrict Litigation established MDL 2846 in the Southern District of Ohio. Judge Edmund A. Sargus, Jr. assigned to oversee.

2019-2022. Active discovery including substantial Bard internal document production. Bellwether case selection process developed.

March 2022. First bellwether trial (Johns v. C.R. Bard) — defense verdict.

August 2022. Second bellwether trial (Milanesi) — $250,000 plaintiff verdict. Specifically that Bard failed to warn about adhesion risks.

July 2022. Rhode Island state court Trevino verdict — $4.8 million plaintiff verdict (later reduced to $4.55 million). The state court verdict provided substantial leverage for ongoing settlement discussions.

November 2023. Third bellwether trial (Stinson v. Davol) — $500,000 plaintiff verdict. The jury found Bard liable for failure to warn doctors.

Late 2023-2024. Settlement negotiations intensified. Settlement mediator appointed.

October 2024. Becton Dickinson announced multi-billion dollar global settlement framework covering approximately 38,000 claims. Settlement structured on points-based allocation system.

January 2025. Qualified Settlement Fund established. Wells Fargo escrow account. Court-appointed Special Masters begin claim review.

March 17, 2025. Original deadline for plaintiffs to submit settlement documentation.

April 2025-Present. Settlement administration proceeding. Case counts remain stable around 23,000-24,000 as administration continues. New claims continue to be filed.

January 2027. Intensive Settlement Process (ISP) scheduled to launch under court-appointed Special Masters. ISP designed to systematically resolve remaining cases.

June 2029. ISP timeline ends. Most cases expected to be fully resolved by this point.

The current procedural phase emphasizes settlement administration rather than continued trial preparation. New cases enter the framework continuously but face the established settlement structure rather than independent litigation paths.

The settlement framework

The global settlement operates through:

Multi-billion dollar fund. Estimated total payout exceeding $1 billion across all qualified plaintiffs. Specific total amount not publicly disclosed but characterized as "multi-billion dollar framework."

Points-based allocation. Each plaintiff's compensation determined by:

Severity of injuries (chronic pain, infection, surgery complications)
Number and complexity of revision surgeries required
Long-term complications and quality of life impact
Age at time of injury (younger plaintiffs adjusted upward for longer duration of complications)
Lost wages or diminished earning capacity
Out-of-pocket medical expenses
Pain and suffering measurement

Compensation tiers. Plaintiffs grouped into tiers based on point totals:

Lower tiers: less severe injuries, more limited compensation
Higher tiers: severe complications, multiple surgeries, permanent impairment
Highest tiers: catastrophic outcomes, permanent disability

Estimated per-plaintiff values. Specific values vary substantially:

Lower tier cases: $25,000-$75,000
Mid tier cases: $75,000-$250,000
Higher tier cases: $250,000-$1,000,000+
Catastrophic cases: potentially $1 million+

Lien resolution. Special Masters address Medicare/Medicaid liens and other healthcare provider claims before final distribution.

Structured settlement options. Some plaintiffs may choose structured settlements for tax and timing advantages.

Qualified Settlement Fund mechanics. Funds deposited in Wells Fargo escrow account. Administration handled by appointed special masters. Tax treatment as QSF preserves plaintiff flexibility.

Eligibility framework

For prospective plaintiffs considering new claims:

Implant identification. Documentation that a Bard or Davol polypropylene hernia mesh was used:

Operative report from hernia repair surgery
Implant card (if provided to patient)
Hospital records identifying the specific product
Surgeon's records
Pathology reports from any subsequent revision surgeries

Qualifying injury. Documented complications including:

Chronic pain
Infection
Mesh migration
Adhesion problems
Bowel obstruction
Recurrent hernia
Need for revision surgery
Other significant complications

Statute of limitations analysis. Most states have 2-4 year limitations periods. The "discovery rule" applies in many jurisdictions — the limitations period begins when the plaintiff knew or should have known about the injury, not when the mesh was first implanted. The discovery rule can substantially extend the effective limitations period.

State-specific analysis. Limitations periods vary by state. Some states have statutes of repose that cap the limitations period regardless of discovery (typically 10-20 years from implantation). State analysis is case-specific.

Documentation requirements:

Hernia repair operative report
Mesh product identification
Subsequent medical records showing complications
Revision surgery records if applicable
Continuing treatment records
Lost wages documentation
Medical expense records

New case framework. New plaintiffs entering the litigation in 2026 face:

The established settlement framework rather than independent litigation
Tier assignment based on individual case facts
Administration timeline within the ISP framework
Potential entry into ISP at January 2027 launch

The strongest typical new case profile:

A patient who had hernia repair surgery with documented Bard polypropylene mesh implantation 5-15 years ago, developed complications requiring revision surgery, has comprehensive medical records documenting the entire timeline, has been recently diagnosed or recently experienced major complications (extending the limitations period under discovery rule), and has substantial documented damages including medical expenses and lost wages.

How Bard compares to other hernia mesh and mass tort litigation

The litigation has distinctive features:

Other hernia mesh MDLs:

Covidien (Medtronic) MDL 3029 — District of Massachusetts before Judge Patti B. Saris. ~2,348 cases as of 2026. First bellwether trial vacated in February 2026. Some plaintiffs' attorneys characterize as "better than Bard" but still in early phase.
Atrium C-Qur — settled in 2021 for approximately $66 million covering 3,000 cases.
Ethicon Physiomesh MDL 2782 — settled, only residual filings continue.

Compared to Roundup litigation with $11+ billion in settlements: Both involve substantial documented internal corporate knowledge. Roundup is further in the settlement process with more comprehensive resolution.

Compared to 3M Combat Arms earplugs MDL 2885 with $6 billion settlement: Both reached substantial settlement frameworks after bellwether trial uncertainty. 3M earplug framework specifically allocated by service period and injury type.

Compared to Philips CPAP MDL 3014 with $1.1 billion settlement: Both involve medical devices with substantial settled exposure. Philips CPAP framework was relatively rapid; Bard has been more extended.

Compared to NEC infant formula MDL 3026 with state court success: Both involve substantial state court verdicts (Bard's $4.8M Trevino verdict in Rhode Island; NEC's $495M Missouri verdict) creating settlement leverage. Bard reached global settlement; NEC remains in bellwether process.

Compared to Ozempic GLP-1 MDL 3094 which is earlier in process: Bard demonstrates the typical mass tort trajectory from bellwether trials through global settlement. GLP-1 is in the bellwether selection phase that Bard completed years ago.

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. Bard represents the relatively mature settlement administration phase that other ongoing mass torts may eventually reach.

Strategic considerations

For plaintiffs already in the settlement framework:

Provide complete documentation for tier assignment. The points-based allocation depends heavily on documentation quality. Provide comprehensive medical records, surgery records, lost wages documentation, and other supporting materials to maximize tier assignment.

Address lien resolution efficiently. Medicare/Medicaid and private insurance liens must be resolved before final distribution. Working efficiently with Special Masters on lien resolution speeds final payment.

Consider structured settlement options. For larger settlements, structured settlement options may provide tax and timing benefits. Discuss with counsel before final distribution.

Plan for the administration timeline. Settlement administration typically extends 2-4 years from QSF establishment. Plan financially for the extended timeline rather than expecting immediate distribution.

For prospective new plaintiffs:

Verify mesh identification. Cases without documented Bard or Davol mesh identification face substantial difficulty. Confirm the specific product used in the hernia repair before pursuing claims.

Engage experienced hernia mesh counsel. The settlement administration framework benefits from counsel familiar with the established procedures. Most plaintiffs' firms work on contingency basis (typically 30-40% of recovery).

Document the medical timeline comprehensively. The strongest cases include:

Original hernia repair operative reports
Mesh product identification (specific model and serial number when available)
Complete medical records following implantation
Documentation of complications and their development
Revision surgery records
Treatment for ongoing complications
Quality of life impact documentation

Watch the statute of limitations carefully. State-specific limitations periods apply. The discovery rule may extend effective limitations periods substantially. Cases involving complications first identified within the last 2-3 years are generally within limitations periods regardless of original implant date.

Be realistic about tier assignment. New plaintiffs enter the established settlement framework. Their compensation will be determined by tier assignment under the points-based system, not by individual trial values.

Address the ISP timeline. The Intensive Settlement Process launches January 2027 with timeline through June 2029. Plan for this extended timeline rather than expecting rapid resolution.

Coordinate with treating physicians. Surgeons who performed original hernia repair, revision surgeons, and ongoing treating physicians are important witnesses. Their support for the case theory and connection to Bard products strengthens cases substantially.

Don't accept inadequate settlements outside the framework. Some private settlements outside the QSF framework may be offered. These typically don't include the full benefit of the established framework. Have any settlement offer evaluated by counsel familiar with the QSF allocations.

Consider state court alternatives. Some plaintiffs may benefit from state court filings rather than MDL participation. The strategic analysis depends on specific case facts and state law.

Plan for the long settlement administration period. From new case filing to final distribution can take 2-4 years given the existing administration timeline.

The Bard hernia mesh litigation represents one of the largest medical device mass torts currently in settlement administration. The bellwether trial outcomes and substantial state court verdicts created the leverage for the multi-billion dollar global settlement framework. The settlement administration through the QSF mechanism and the upcoming Intensive Settlement Process provides a structured path to resolution for the substantial pool of plaintiffs with documented Bard polypropylene mesh complications. For new plaintiffs with qualifying injuries, the framework provides paths to compensation through tier assignment under the points-based allocation system. The work for plaintiffs (both current and prospective) is in comprehensive documentation of medical timeline, engagement with experienced counsel, navigation of the established procedural framework, and patience with the extended administration timeline. For plaintiffs with strong documentation and serious injuries, the framework can produce substantial compensation that addresses the medical expenses, lost wages, and quality of life impact caused by the alleged polypropylene mesh failures. The cumulative settlement payout of $1+ billion across the substantial plaintiff population represents one of the more significant medical device mass tort resolutions in recent history.